Pharmaceutical News

RSS

Vitamin D supplements show promise to counter the adverse effects of diabetes drug on bone health

Vitamin D supplementation may help offset damaging bone loss that occurs in some people who take canagliflozin, a commonly prescribed diabetes drug.

27 Jun 2022

Bisphosphonates appear to improve COVID-19 exposure outcomes

A new retrospective study examines the effect of bisphosphonates on COVID-19 outcomes.

27 Jun 2022

MD Anderson announces collaborative alliance with Turning Point Therapeutics to advance new treatment options for cancer patients

The University of Texas MD Anderson Cancer Center and Turning Point Therapeutics, Inc., today announced a strategic research and development alliance to expand the evaluation of two of Turning Point's investigational small molecules focusing on precision medicine targets well known in oncology.

24 Jun 2022

Updated Cochrane Review: No evidence to support the use of ivermectin for treating COVID-19 infection

There remains no evidence to support the use of ivermectin for treating or preventing COVID-19 infection, state the authors of an updated Cochrane Review, which now contains 11 trials across 3409 people.

24 Jun 2022

COVID-19 rebound risks similar for Paxlovid and Molnupiravir

In a recent article posted to the medRxiv* preprint server, investigators in the United States illustrated that rebound of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can occur in some patients following molnupiravir and Paxlovid SARS-CoV-2 therapy.

23 Jun 2022

Research assesses ability of SARS‐CoV‐2‐neutralising mAbs to prevent COVID‐19

In a recent study published in the Cochrane Library, researchers searched multiple databases to identify randomized controlled trials (RCTs) that evaluated severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐neutralizing monoclonal antibodies (mAbs).

23 Jun 2022

Paxlovid is shown to be effective in treating COVID-19

In a recent Morbidity and Mortality Weekly Report (MMWR) published on the United States Center for Disease Control and Prevention (US-CDC) website, researchers described cases of coronavirus disease 2019 (COVID-19)–related hospitalizations and emergency department (ED) visits in five to 15 days following Paxlovid (Nirmatrelvir/ritonavir ) treatment.

22 Jun 2022

INTEGRA’s PIPETBOY acu 2 pipette controller takes a deep dive into cellular physics

...

From INTEGRA Biosciences 22 Jun 2022

New pain medications with high abuse potential more likely to be successfully developed

Despite the prevalence and societal costs of pain in the United States, investment in pain medication development is low, due in part to poor understanding of the probability of successful development of such medications

21 Jun 2022

Insufficient drug exposure most likely to cause COVID-19 rebound

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals.

21 Jun 2022

Study finds traditional African drug inhibits growth of SARS-CoV-2 infection

Researchers evaluated the efficacy of PHELA, a traditional African drug, against SARS-CoV-2 in vitro.

21 Jun 2022

Real-world study shows Paxlovid associated with lower hospitalization rates

In a recent study posted to the medRxiv* pre-print server, researchers investigated the effectiveness of nirmatrelvir plus ritonavir in preventing hospitalizations among individuals aged 50 or older and vaccinated for coronavirus disease 2019 (COVID-19).

20 Jun 2022

Model predicts effectiveness of COVID-19 vaccines against circulating SARS-CoV-2 variants

In a recent study published in the journal Nature Medicine, researchers assessed the coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) against symptomatic infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) and variants of interest (VOIs) by genetic mismatch/distance (GD) analysis.

20 Jun 2022

How effective are mRNA COVID-19 vaccine boosters against Omicron?

In a recent study posted to the medRxiv* preprint server, researchers University of Washington, University of Michigan, Duke University, and Veterans Affairs Portland Healthcare System assessed the effectiveness of the coronavirus disease 2019 (COVID-19) booster vaccines.

19 Jun 2022

A proposal to import drugs from other countries creates an unusual alliance in the Senate

Harmony is not often found between two of the most boisterous senators on Capitol Hill, Bernie Sanders (I-Vt.) and Rand Paul (R-Ky.).

17 Jun 2022

Drugs used to prevent bone loss may help lower ovarian cancer risk

Medicines used to prevent bone loss may help lower the risk of ovarian cancer according to research by The University of Queensland.

16 Jun 2022

At a Bay Area ‘test-to-treat’ site, few takers for free antivirals

After avoiding movie theaters, restaurants, and gyms for more than two years, Helen Ho decided to take her first big risk since the start of the pandemic to attend her graduation.

16 Jun 2022

Study confirms heightened protection from Omicron-associated hospitalizations by COVID boosters

In a recent article posted to the medRxiv* preprint server, scientists assessed the efficacy of the primary and boosted regimens of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations in preventing SARS-CoV-2 Omicron-linked hospitalizations in the United States (US).

16 Jun 2022

Cost of brand-name antiseizure medications increased by 277% from 2010 to 2018, study finds

The cost of brand-name drugs for epilepsy increased by 277% from 2010 to 2018, according to a study published in the June 15, 2022, online issue of Neurology, the medical journal of the American Academy of Neurology.

16 Jun 2022

Chemical synthesis, properties, and molecular modeling studies of spiro-indole compounds

In a recent study under review at the Scientific Reports journal and currently posted to the Research Square* preprint server, researchers synthesized and evaluated the antitumoral (against several cancer cell lines) and antiviral [against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)] properties of 3-spiro-indolin-2-ones.

15 Jun 2022

Previous
1
...
75
76
77
78
79
80
81
...
1434
Next

Pharmaceutical News

Vitamin D supplements show promise to counter the adverse effects of diabetes drug on bone health

Bisphosphonates appear to improve COVID-19 exposure outcomes

MD Anderson announces collaborative alliance with Turning Point Therapeutics to advance new treatment options for cancer patients

Updated Cochrane Review: No evidence to support the use of ivermectin for treating COVID-19 infection

COVID-19 rebound risks similar for Paxlovid and Molnupiravir

Research assesses ability of SARS‐CoV‐2‐neutralising mAbs to prevent COVID‐19

Paxlovid is shown to be effective in treating COVID-19

INTEGRA’s PIPETBOY acu 2 pipette controller takes a deep dive into cellular physics

New pain medications with high abuse potential more likely to be successfully developed

Insufficient drug exposure most likely to cause COVID-19 rebound

Study finds traditional African drug inhibits growth of SARS-CoV-2 infection

Real-world study shows Paxlovid associated with lower hospitalization rates

Model predicts effectiveness of COVID-19 vaccines against circulating SARS-CoV-2 variants

How effective are mRNA COVID-19 vaccine boosters against Omicron?

A proposal to import drugs from other countries creates an unusual alliance in the Senate

Drugs used to prevent bone loss may help lower ovarian cancer risk

At a Bay Area ‘test-to-treat’ site, few takers for free antivirals

Study confirms heightened protection from Omicron-associated hospitalizations by COVID boosters

Cost of brand-name antiseizure medications increased by 277% from 2010 to 2018, study finds

Chemical synthesis, properties, and molecular modeling studies of spiro-indole compounds

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News